

EDITOR

Douglas K. McCormick

RESEARCH EDITOR

Harvey Bialy

SENIOR EDITORS

Jennifer Van Brunt

Arthur Klausner

CONTRIBUTING EDITORS

Peter Newmark

Jeffrey L. Fox

EDITORIAL ASSISTANT

Caroline Schneider

ART DIRECTOR

Dennis Ahlgrim

PRODUCTION MANAGER

Donna Zuckerman

PUBLISHER

Gary M. Rekstad

ADVERTISING SALES MANAGER

George F. Cominsky

EUROPEAN ADVERTISING**SALES MANAGER**

Hilary Turnbull

CIRCULATION DIRECTOR

James Skowrenski

FULFILLMENT MANAGER

W. Paige Beaver

EDITORIAL CORRESPONDENCE:

BIO/TECHNOLOGY, 65 Bleecker St., New York, NY 10012. Telephone: (212) 477-9600. Telex: 668497UW.
 BIO/TECHNOLOGY, 4 Little Essex Street, London WC2R 3LF. Telephone: (01) 836 6633. Telex: 262024.

SCIENTIFIC ADVISORY BOARD**CHAIRMAN**

George Poste, Smith Kline & French
 Pharmaceutical Development

Mary-Dell Chilton, CIBA-Geigy
 Plant Molecular Biology

Carlo Croce, Wistar Institute
 Monoclonal Antibodies

Arnold Demain, MIT
 Secondary Metabolism and Fermentation

Stanley Falkow, Stanford
 Medicine and Vaccine Development

David Goeddel, Genentech
 Recombinant DNA Products

Benjamin Hall, Univ. of Washington
 Yeast Genetics

Ernest Jaworski, Monsanto
 Plant Biotechnology

Ephraim Katchalski-Katzir
 Tel Aviv University
 Immobilized Enzymes and Polymers

Allen Laskin, N.J. Center for Advanced
 Biotechnology and Medicine
 Hydrocarbons and Polysaccharides

Malcolm Lilly, University College
 London, Biochemical Engineering

David Mount, University of Arizona
 Computer Applications

Carl-Gustaf Rosen, Alfa-Laval
 Biochemical Engineering

Yukio Sugino, Takeda
 Cancer Chemotherapy

Lemuel B. Wingard, University of
 Pittsburgh, Enzyme Engineering
 and Biosensors

To supplement coverage of Japanese developments, BIO/TECHNOLOGY has an editorial liaison with the editorial staff of Japan Chemical Daily, Ltd. and Japan Chemical Week.

EVERY SIX MINUTES

At the end of May, the U.S. Food and Drug Administration's advisory committee on cardio-renal medicine issued its recommendations on streptokinase and tissue-type plasminogen activator (t-PA)—clot-dissolving agents for emergency treatment of acute myocardial infarction. The headline on this month's news story sums it up: "Streptokinase, Yes; Genentech's t-PA, No."

No, we don't understand it either. The FDA advisory panel cited the absence of evidence on t-PA's effects on overall patient mortality—in contrast to the streptokinase data, which include a multi-year, multi-center Italian study showing that streptokinase treatment reduced patient mortality by 18 percent. Other information, however, strongly suggests that t-PA is the better drug.

Just this April, F. H. Sheehan, Eugene Braunwald, and their co-authors published "The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) trial" (*Circulation* 75(4):817-829, 1987). This followed earlier reports (*New England Journal of Medicine*, 312(14):932-936, 1985) that the TIMI researchers had stopped giving streptokinase in comparative trials because t-PA's overwhelming superiority made it unethical to subject patients to the greater risk.

As the TIMI papers report, quick treatment with t-PA doubled a patient's chances of reperfusion—of regaining blood flow to the heart. About two-thirds of the patients receiving t-PA achieve reperfusion; only about one-third of streptokinase-treated patients enjoy similar results.

The news is not completely rosy, of course. Restored heart function is not synonymous with reperfusion, though the faster the thrombolytic treatment the greater the likelihood of regaining some use of the affected areas.

The Italian study, cited by the FDA panel, found that 21-day mortality rates in patients treated with streptokinase were 10.7 percent, compared with 13 percent in the control group—an 18 percent relative reduction (Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI), *The Lancet*, (8478):397-402, 1986). In a much smaller, uncontrolled U.S. study (*Annals of Emergency Medicine* 16(3):243-247, 1987), D. G. Walsh and co-workers found that immediate t-PA treatment substantially reduced heart clots in 76 percent of their 105 emergency-room patients. The overall 30-day survival rate was 94 percent—a 6 percent mortality rate. That scarcely indicates a grave, lurking danger against which America's heart-attack sufferers must be protected.

Not that either of the fibrinolytic agents is without risks. Treatment can lower the overall levels of plasma fibrinogen and produce hemorrhages. Patients treated with t-PA commonly develop hematomas, and about a quarter need transfusions. In the judgment of those conducting the TIMI trials, t-PA and streptokinase present similar risks to the patient. Indeed, according to Herman Gold (Harvard Medical School), streptokinase is, if anything, riskier than t-PA. Streptokinase is antigenic, pyrogenic, and can, he says, sometimes cause systemic lytic complications. Moreover, new preparations of t-PA promise even fewer side-effects and higher success rates—reperfusion in up to 86% of patients, according to Gold and fellow researchers at Massachusetts General Hospital (H. J. Garabedian, H. K. Gold, et al., *J. Am. Coll. Cardiol.* 9(3):599-607, 1987).

By the time this note sees print, the FDA—habitually, in its dealings with the biotechnologies, the most enlightened federal agency—may already have overridden the advice of its advisors. If it does, it will undoubtedly be criticized for knuckling under to industry pressure. But there are more pressing reasons for ignoring bad counsel: While we wait for more information, the meter is still ticking. Ischemic heart disease kills about half-a-million Americans each year. Most of these die of acute myocardial infarction. Some back-of-the-envelope extrapolation of the mortality rates in the GISSI and Walsh studies (conducted, admittedly, on very different numbers of patients in very different areas) shows that we pay a grim price for delay: In the U.S. alone, every three to six minutes, death claims one more heart-attack victim that t-PA might have saved.

—Douglas McCormick